Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

September 12, 2012

Driving Translational Imaging to a Drug Industry Standard:
Case Studies in Glioblastoma and Other Clinically Predictive Cancer Models

Speakers for this Event: 
  • Jim Dougherty, MD, General Partner, Arcus Ventures, and former Deputy Physician-in Chief for
        Clinical Affairs at Memorial Sloan-Kettering Cancer Center (MSKCC)  
    Learn More
  • Wilbur R. Leopold III, Ph.D., VP, R&D, Molecular Imaging Inc.  Learn More
  • John L. Chunta, PhD, Senior Imaging Scientist, Molecular Imaging Inc.  Learn More
  • Medical imaging technologies can facilitate drug discovery, efficacy evaluation, and translation into the clinic. Now a maturing platform, molecular imaging is the catalyst for a new standard of how drug candidates are evaluated and advanced into trials.

    By providing clinically translatable biomarkers as an accompaniment to standard measures of response, imaging leverages and amplifies the valuable data gathered during earlier stages of discovery and efficacy evaluation. A significant determinant of the clinical applicability of the obtained biomarker data is preclinical models that it is derived from. As a cornerstone of modern cancer drug discovery, a diverse array of preclinical cancer models are available, each with unique advantages and shortcomings.

    Preclinical models are often criticized as being poorly predictive of success in the clinic. By choosing the proper models and pairing them with advancing imaging technologies, their predictive power can be improved.

    We will discuss fundamental principles of preclinical modeling in cancer and the specific roles that imaging can play in improving the predictive power for clinical success, formulating a new standard for drug development, with particular reference to gliomas as case studies.


    Senior executives and senior scientists involved in the research & development of oncology drugs, including those in the following functional areas:

    • Pre-clinical and clinical development
    • Pre-clinical and clinical pharmaclology
    • Pre-clinical and clinical research
    • Pre-clinical and clinical drug development
    • Discovery and development scientists

    This presentation will also be of interest to those involved in biomarker discovery & development.


    Jim Dougherty, MD, General Partner, Arcus Ventures, and former Deputy Physician-in Chief for Clinical Affairs a Memorial Sloan-Kettering Cancer Center (MSKCC)

    Jim Dougherty is a co-founder and general partner of Arcus Ventures Fund (AVF), an oncology focused venture capital fund based in New York City. AVF was founded in 2007 and invests in therapeutics, devices, diagnostics and services related to cancer. He is a medical oncologist trained at Memorial Sloan Kettering Cancer Center, where he was also a faculty member including the administrative role of Deputy Physician in Chief for 5 years overseeing clinical operations for the center. He is a graduate of Georgetown University, Hershey Medical School of Penn State University and received an MBA from the Wharton School of the University of Pennsylvania.

    Wilbur R. Leopold III, Ph.D., VP, R&D, Molecular Imaging Inc.

    Dr. Leopold has been the principal scientist and program leader for the discovery and/or development of more than 15 anticancer agents, which have advanced to clinical trials. He served as the initial President and CEO of Molecular Imaging Research and led the company’s growth and resultant sale to Charles River Laboratory in 2008. In 2011, Dr. Leopold co-led the re-establishment of Molecular Imaging as an independent CRO. Prior to Molecular Imaging, Dr. Leopold led the growth of the cancer drug discovery effort at Parke-Davis/Pfizer in Ann Arbor. He led the transition to a focus on novel molecular targets, and on the application and automation of preclinical pharmacodynamic assays to speed drug discovery. Dr. Leopold’s personal research interests are centered on the use of preclinical in vivo models to predict clinical outcomes.

    A prolific author, Dr. Leopold holds three patents and is a reviewer for several renowned scientific journals. He is an Adjunct Professor of Medicinal Chemistry at the University of Michigan and a member of Purdue University Cancer Center Molecular Discovery and Evaluation Shared Resource Advisory.

    Dr. Leopold received his Ph.D. in Oncology from University of Wisconsin Medical School, a M.S. in Biochemistry and a B.S. in Chemical Engineering from the University of Illinois.

    John L. Chunta, PhD, Senior Imaging Scientist, Molecular Imaging Inc

    Dr. Chunta received his Ph.D. in Anatomy and Cell Biology from Wayne State University Medical School, Detroit, MI, and a B.A. in Biology from Franciscan University of Steubenville, Steubenville, OH. Dr. Chunta recently joined Molecular Imaging in the fall of 2011 as a Senior Imaging Scientist. His background is primarily in cancer biology and tumor microenvironment, and multimodality preclinical imaging, with particular emphasis on PET/CT. Before joining Molecular Imaging, Dr. Chunta most recently managed the preclinical imaging facility as a Research Associate II in the Department of Radiation Oncology at Beaumont Health System and an Assistant Professor of Radiation Oncology, Oakland University William Beaumont School of Medicine. Prior to this, he was a Postdoctoral Fellow and a Research Associate I in the Department of Radiation Oncology at Beaumont Health System.


    Molecular Imaging is the only Contract Research Organization (CRO) dedicated to collaborate closely with our clients to answer their small animal in-vivo multi-modality imaging needs (anatomical, functional, molecular). The combination and depth of experience in our pharmacology and imaging teams is what makes us different and a valued partner to the pharmaceutical industry.

    Imaging modalities currently include small animal MRI, PET , CT, bioluminescence, fluorescence, FMT, DEXA, 2D X-ray and in the near future we will be adding many exciting new modalities. Molecular Imaging offers pharmacology models primarily in support of Oncology and Inflammation research. We are also rapidly expanding the number of models available across a range of therapeutic areas through our own R&D program and in collaboration with our clients.

    With nearly a decade of CRO imaging experience, Molecular Imaging combines broad protocol and model validation, optimized image acquisition and analysis throughput, with strong client-oriented project management.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Copyright © 2016-2017 Honeycomb Worldwide Inc.